Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?
Identifieur interne : 000913 ( Istex/Corpus ); précédent : 000912; suivant : 000914Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?
Auteurs : Roslyn M. BillSource :
- Journal of Pharmacy and Pharmacology [ 0022-3573 ] ; 2015-03.
Abstract
Objectives: Recombinant protein subunit vaccines are formulated using protein antigens that have been synthesized in heterologous host cells. Several host cells are available for this purpose, ranging from Escherichia coli to mammalian cell lines. This article highlights the benefits of using yeast as the recombinant host. Key findings: The yeast species, Saccharomyces cerevisiae and Pichia pastoris, have been used to optimize the functional yields of potential antigens for the development of subunit vaccines against a wide range of diseases caused by bacteria and viruses. Saccharomyces cerevisiae has also been used in the manufacture of 11 approved vaccines against hepatitis B virus and one against human papillomavirus; in both cases, the recombinant protein forms highly immunogenic virus‐like particles. Summary: Advances in our understanding of how a yeast cell responds to the metabolic load of producing recombinant proteins will allow us to identify host strains that have improved yield properties and enable the synthesis of more challenging antigens that cannot be produced in other systems. Yeasts therefore have the potential to become important host organisms for the production of recombinant antigens that can be used in the manufacture of subunit vaccines or in new vaccine development.
Url:
DOI: 10.1111/jphp.12353
Links to Exploration step
ISTEX:F6E11952D083724F50B9D5C02407D6ED37EEEB39Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?</title><author><name sortKey="Bill, Roslyn M" sort="Bill, Roslyn M" uniqKey="Bill R" first="Roslyn M." last="Bill">Roslyn M. Bill</name><affiliation><mods:affiliation>School of Life and Health Sciences, Aston University, Birmingham, UK</mods:affiliation></affiliation><affiliation><mods:affiliation>Roslyn M. Bill, School of Life and Health Sciences, Aston University, Aston Triangle, B4 7ET Birmingham, UK.E‐mail:</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: r.m.bill@aston.ac.uk</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F6E11952D083724F50B9D5C02407D6ED37EEEB39</idno><date when="2015" year="2015">2015</date><idno type="doi">10.1111/jphp.12353</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-KM1XJXHK-3/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000913</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000913</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?</title><author><name sortKey="Bill, Roslyn M" sort="Bill, Roslyn M" uniqKey="Bill R" first="Roslyn M." last="Bill">Roslyn M. Bill</name><affiliation><mods:affiliation>School of Life and Health Sciences, Aston University, Birmingham, UK</mods:affiliation></affiliation><affiliation><mods:affiliation>Roslyn M. Bill, School of Life and Health Sciences, Aston University, Aston Triangle, B4 7ET Birmingham, UK.E‐mail:</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: r.m.bill@aston.ac.uk</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Pharmacy and Pharmacology</title><title level="j" type="sub">Enhancing Vaccine Design Strategies. Guest Editors: Yvonne Perrie, Helen R. Griffiths and David Jones</title><title level="j" type="alt">JOURNAL OF PHARMACY AND PHARMACOLOGY</title><idno type="ISSN">0022-3573</idno><idno type="eISSN">2042-7158</idno><imprint><biblScope unit="vol">67</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="319">319</biblScope><biblScope unit="page" to="328">328</biblScope><biblScope unit="page-count">10</biblScope><date type="published" when="2015-03">2015-03</date></imprint><idno type="ISSN">0022-3573</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-3573</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Objectives: Recombinant protein subunit vaccines are formulated using protein antigens that have been synthesized in heterologous host cells. Several host cells are available for this purpose, ranging from Escherichia coli to mammalian cell lines. This article highlights the benefits of using yeast as the recombinant host. Key findings: The yeast species, Saccharomyces cerevisiae and Pichia pastoris, have been used to optimize the functional yields of potential antigens for the development of subunit vaccines against a wide range of diseases caused by bacteria and viruses. Saccharomyces cerevisiae has also been used in the manufacture of 11 approved vaccines against hepatitis B virus and one against human papillomavirus; in both cases, the recombinant protein forms highly immunogenic virus‐like particles. Summary: Advances in our understanding of how a yeast cell responds to the metabolic load of producing recombinant proteins will allow us to identify host strains that have improved yield properties and enable the synthesis of more challenging antigens that cannot be produced in other systems. Yeasts therefore have the potential to become important host organisms for the production of recombinant antigens that can be used in the manufacture of subunit vaccines or in new vaccine development.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>recombinant</json:string><json:string>vaccine</json:string><json:string>subunit</json:string><json:string>pastoris</json:string><json:string>cerevisiae</json:string><json:string>coli</json:string><json:string>pichia</json:string><json:string>immunogenic</json:string><json:string>hbsag</json:string><json:string>saccharomyces</json:string><json:string>pichia pastoris</json:string><json:string>plasmodium</json:string><json:string>biotechnol</json:string><json:string>recombinant protein</json:string><json:string>eukaryotic</json:string><json:string>biologicals</json:string><json:string>pharmacology</json:string><json:string>glaxosmithkline</json:string><json:string>roslyn</json:string><json:string>royal pharmaceutical society</json:string><json:string>papillomavirus</json:string><json:string>escherichia</json:string><json:string>causative agent</json:string><json:string>microb</json:string><json:string>dengue</json:string><json:string>capsid</json:string><json:string>microb cell fact</json:string><json:string>vlps</json:string><json:string>saccharomyces cerevisiae</json:string><json:string>immunogenicity</json:string><json:string>host cell</json:string><json:string>yeast</json:string><json:string>insect cell</json:string><json:string>falciparum</json:string><json:string>biol</json:string><json:string>recombinant antigen</json:string><json:string>glycoprotein</json:string><json:string>pasteur</json:string><json:string>vaccine development</json:string><json:string>microbe</json:string><json:string>subunit vaccine</json:string><json:string>lyme</json:string><json:string>microbiol</json:string><json:string>escherichia coli</json:string><json:string>adjuvant</json:string><json:string>recombinant protein subunit vaccine</json:string><json:string>vaccine candidate</json:string><json:string>causative</json:string><json:string>lyme disease</json:string><json:string>virus hepatitis</json:string><json:string>human papillomavirus type</json:string><json:string>fusion protein</json:string><json:string>recombinant protein production</json:string><json:string>mammalian cell line</json:string><json:string>recombinant protein antigen</json:string><json:string>sanofi pasteur</json:string><json:string>surface antigen</json:string><json:string>appl microbiol biotechnol</json:string><json:string>influenza virus</json:string><json:string>hepatitis</json:string><json:string>protein</json:string><json:string>borrelia burgdorferi</json:string><json:string>recombinant subunit vaccine</json:string><json:string>recombinant host</json:string><json:string>glaxosmithkline biologicals</json:string><json:string>recent advance</json:string><json:string>malaria vaccine</json:string><json:string>antibody response</json:string><json:string>envelope domain</json:string><json:string>plasmodium falciparum</json:string><json:string>recombinant host cell</json:string><json:string>pubmed central database</json:string><json:string>major capsid protein</json:string><json:string>wide range</json:string><json:string>plasmodium vivax</json:string><json:string>circumsporozoite protein</json:string><json:string>protein expr purif</json:string><json:string>immunogenic characterization</json:string><json:string>pharmaceutical</json:string><json:string>antigen</json:string></teeft></keywords><author><json:item><name>Roslyn M. Bill</name><affiliations><json:string>School of Life and Health Sciences, Aston University, Birmingham, UK</json:string><json:string>Roslyn M. Bill, School of Life and Health Sciences, Aston University, Aston Triangle, B4 7ET Birmingham, UK.E‐mail:</json:string><json:string>E-mail: r.m.bill@aston.ac.uk</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Pichia pastoris</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>recombinant antigen</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Saccharomyces cerevisiae</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>yeast</value></json:item></subject><articleId><json:string>JPHP12353</json:string></articleId><arkIstex>ark:/67375/WNG-KM1XJXHK-3</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>Objectives: Recombinant protein subunit vaccines are formulated using protein antigens that have been synthesized in heterologous host cells. Several host cells are available for this purpose, ranging from Escherichia coli to mammalian cell lines. This article highlights the benefits of using yeast as the recombinant host. Key findings: The yeast species, Saccharomyces cerevisiae and Pichia pastoris, have been used to optimize the functional yields of potential antigens for the development of subunit vaccines against a wide range of diseases caused by bacteria and viruses. Saccharomyces cerevisiae has also been used in the manufacture of 11 approved vaccines against hepatitis B virus and one against human papillomavirus; in both cases, the recombinant protein forms highly immunogenic virus‐like particles. Summary: Advances in our understanding of how a yeast cell responds to the metabolic load of producing recombinant proteins will allow us to identify host strains that have improved yield properties and enable the synthesis of more challenging antigens that cannot be produced in other systems. Yeasts therefore have the potential to become important host organisms for the production of recombinant antigens that can be used in the manufacture of subunit vaccines or in new vaccine development.</abstract><qualityIndicators><score>9.328</score><pdfWordCount>5875</pdfWordCount><pdfCharCount>42359</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>10</pdfPageCount><pdfPageSize>595.276 x 782.333 pts</pdfPageSize><pdfWordsPerPage>588</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>194</abstractWordCount><abstractCharCount>1312</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?</title><genre><json:string>review-article</json:string></genre><host><title>Journal of Pharmacy and Pharmacology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)2042-7158</json:string></doi><issn><json:string>0022-3573</json:string></issn><eissn><json:string>2042-7158</json:string></eissn><publisherId><json:string>JPHP</json:string></publisherId><volume>67</volume><issue>3</issue><pages><first>319</first><last>328</last><total>10</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>REVIEW</value></json:item><json:item><value>REVIEW</value></json:item></subject></host><ark><json:string>ark:/67375/WNG-KM1XJXHK-3</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - pharmacology & pharmacy</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - pharmacology & pharmacy</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string><json:string>3 - Pharmaceutical Science</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Pharmacology, Toxicology and Pharmaceutics</json:string><json:string>3 - Pharmacology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences biologiques fondamentales et appliquees. psychologie</json:string></inist></categories><publicationDate>2015</publicationDate><copyrightDate>2015</copyrightDate><doi><json:string>10.1111/jphp.12353</json:string></doi><id>F6E11952D083724F50B9D5C02407D6ED37EEEB39</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-KM1XJXHK-3/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-KM1XJXHK-3/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-KM1XJXHK-3/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?</title><title level="a" type="short">Recombinant protein subunit vaccines</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher ref="https://scientific-publisher.data.istex.fr/ark:/67375/H02-QW5Q88H5-V">Wiley Publishing Ltd</publisher><availability><licence>© 2014 Royal Pharmaceutical Society</licence></availability><date type="published" when="2015-03"></date></publicationStmt><notesStmt><note type="content-type" subtype="review-article" source="reviewArticle" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="review-article"><analytic><title level="a" type="main">Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?</title><title level="a" type="short">Recombinant protein subunit vaccines</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Roslyn M.</forename><surname>Bill</surname></persName><affiliation><orgName type="division">School of Life and Health Sciences</orgName><orgName type="institution">Aston University</orgName><address><settlement>Birmingham</settlement><country key="GB" xml:lang="en">UNITED KINGDOM</country></address></affiliation></author><idno type="istex">F6E11952D083724F50B9D5C02407D6ED37EEEB39</idno><idno type="ark">ark:/67375/WNG-KM1XJXHK-3</idno><idno type="DOI">10.1111/jphp.12353</idno><idno type="unit">JPHP12353</idno><idno type="toTypesetVersion">file://JPHP.JPHP12353.pdf</idno></analytic><monogr><title level="j" type="main">Journal of Pharmacy and Pharmacology</title><title level="j" type="sub">Enhancing Vaccine Design Strategies. Guest Editors: Yvonne Perrie, Helen R. Griffiths and David Jones</title><title level="j" type="alt">JOURNAL OF PHARMACY AND PHARMACOLOGY</title><idno type="pISSN">0022-3573</idno><idno type="eISSN">2042-7158</idno><idno type="book-DOI">10.1111/(ISSN)2042-7158</idno><idno type="book-part-DOI">10.1111/jphp.2015.67.issue-3</idno><idno type="product">JPHP</idno><imprint><biblScope unit="vol">67</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="319">319</biblScope><biblScope unit="page" to="328">328</biblScope><biblScope unit="page-count">10</biblScope><date type="published" when="2015-03"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract style="main"><head>Abstract</head><head>Objectives</head><p>Recombinant protein subunit vaccines are formulated using protein antigens that have been synthesized in heterologous host cells. Several host cells are available for this purpose, ranging from <hi rend="fc"><hi rend="italic">E</hi></hi><hi rend="italic">scherichia coli</hi> to mammalian cell lines. This article highlights the benefits of using yeast as the recombinant host.</p><head>Key findings</head><p>The yeast species, <hi rend="fc"><hi rend="italic">S</hi></hi><hi rend="italic">accharomyces cerevisiae</hi> and <hi rend="fc"><hi rend="italic">P</hi></hi><hi rend="italic">ichia pastoris</hi>, have been used to optimize the functional yields of potential antigens for the development of subunit vaccines against a wide range of diseases caused by bacteria and viruses. <hi rend="fc"><hi rend="italic">S</hi></hi><hi rend="italic">accharomyces cerevisiae</hi> has also been used in the manufacture of 11 approved vaccines against hepatitis <hi rend="fc">B</hi> virus and one against human papillomavirus; in both cases, the recombinant protein forms highly immunogenic virus‐like particles.</p><head>Summary</head><p>Advances in our understanding of how a yeast cell responds to the metabolic load of producing recombinant proteins will allow us to identify host strains that have improved yield properties and enable the synthesis of more challenging antigens that cannot be produced in other systems. Yeasts therefore have the potential to become important host organisms for the production of recombinant antigens that can be used in the manufacture of subunit vaccines or in new vaccine development.</p></abstract><textClass><keywords><term xml:id="jphp12353-kwd-0001"><hi rend="fc"><hi rend="italic">P</hi></hi><hi rend="italic">ichia pastoris</hi></term><term xml:id="jphp12353-kwd-0002">recombinant antigen</term><term xml:id="jphp12353-kwd-0003"><hi rend="fc"><hi rend="italic">S</hi></hi><hi rend="italic">accharomyces cerevisiae</hi></term><term xml:id="jphp12353-kwd-0004">yeast</term></keywords><keywords rend="tocHeading1"><term>REVIEW</term></keywords><keywords rend="articleCategory"><term>REVIEW</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-KM1XJXHK-3/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component type="serialArticle" version="2.0" xml:id="jphp12353" xml:lang="en"><header><publicationMeta level="product"><doi origin="wiley">10.1111/(ISSN)2042-7158</doi><issn type="print">0022-3573</issn><issn type="electronic">2042-7158</issn><idGroup><id type="product" value="JPHP"></id></idGroup><titleGroup><title sort="JOURNAL OF PHARMACY AND PHARMACOLOGY" type="main">Journal of Pharmacy and Pharmacology</title><title type="short">J Pharm Pharmacol</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi>10.1111/jphp.2015.67.issue-3</doi><titleGroup><title type="specialIssueTitle">Enhancing Vaccine Design Strategies. Guest Editors: Yvonne Perrie, Helen R. Griffiths and David Jones</title></titleGroup><copyright ownership="thirdParty">Copyright © 2015 Royal Pharmaceutical Society</copyright><numberingGroup><numbering number="67" type="journalVolume">67</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2015-03">March 2015</coverDate></publicationMeta><publicationMeta level="unit" position="40" status="forIssue" type="reviewArticle"><doi>10.1111/jphp.12353</doi><idGroup><id type="unit" value="JPHP12353"></id></idGroup><countGroup><count number="10" type="pageTotal"></count></countGroup><titleGroup><title type="tocHeading1">REVIEW</title><title type="articleCategory">REVIEW</title></titleGroup><copyright ownership="thirdParty">© 2014 Royal Pharmaceutical Society</copyright><eventGroup><event agent="bestset" date="2014-11-05" type="xmlCreated"></event><event date="2014-06-10" type="manuscriptReceived"></event><event date="2014-10-18" type="manuscriptAccepted"></event><event type="publishedOnlineEarlyUnpaginated" date="2014-12-31"></event><event type="firstOnline" date="2014-12-31"></event><event type="publishedOnlineFinalForm" date="2015-03-26"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.7.2 mode:FullText" date="2016-01-06"></event></eventGroup><numberingGroup><numbering type="pageFirst">319</numbering><numbering type="pageLast">328</numbering></numberingGroup><correspondenceTo><lineatedText><line><b>Correspondence</b></line><line>Roslyn M. Bill, School of Life and Health Sciences, Aston University, Aston Triangle, B4 7ET Birmingham, UK.</line><line>E‐mail: <email>r.m.bill@aston.ac.uk</email></line></lineatedText></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file://JPHP.JPHP12353.pdf"></link></linkGroup></publicationMeta><contentMeta><titleGroup><title type="short">Recombinant protein subunit vaccines</title><title type="shortAuthors">Roslyn <fc>M</fc>. <fc>B</fc>ill</title><title type="main">Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?</title></titleGroup><creators><creator affiliationRef="#jphp12353-aff-0001" corresponding="yes" creatorRole="author" xml:id="jphp12353-cr-0001"><personName><givenNames>Roslyn M.</givenNames><familyName>Bill</familyName></personName></creator></creators><affiliationGroup><affiliation countryCode="GB" xml:id="jphp12353-aff-0001"><orgDiv>School of Life and Health Sciences</orgDiv><orgName>Aston University</orgName><address><city>Birmingham</city><country>UK</country></address></affiliation></affiliationGroup><keywordGroup type="author"><keyword xml:id="jphp12353-kwd-0001"><fc><i>P</i></fc><i>ichia pastoris</i></keyword><keyword xml:id="jphp12353-kwd-0002">recombinant antigen</keyword><keyword xml:id="jphp12353-kwd-0003"><fc><i>S</i></fc><i>accharomyces cerevisiae</i></keyword><keyword xml:id="jphp12353-kwd-0004">yeast</keyword></keywordGroup><abstractGroup><abstract type="main"><title type="main">Abstract</title><section xml:id="jphp12353-sec-1001"><title type="main">Objectives</title><p>Recombinant protein subunit vaccines are formulated using protein antigens that have been synthesized in heterologous host cells. Several host cells are available for this purpose, ranging from <fc><i>E</i></fc><i>scherichia coli</i> to mammalian cell lines. This article highlights the benefits of using yeast as the recombinant host.</p></section><section xml:id="jphp12353-sec-1002"><title type="main">Key findings</title><p>The yeast species, <fc><i>S</i></fc><i>accharomyces cerevisiae</i> and <fc><i>P</i></fc><i>ichia pastoris</i>, have been used to optimize the functional yields of potential antigens for the development of subunit vaccines against a wide range of diseases caused by bacteria and viruses. <fc><i>S</i></fc><i>accharomyces cerevisiae</i> has also been used in the manufacture of 11 approved vaccines against hepatitis <fc>B</fc> virus and one against human papillomavirus; in both cases, the recombinant protein forms highly immunogenic virus‐like particles.</p></section><section xml:id="jphp12353-sec-1003"><title type="main">Summary</title><p>Advances in our understanding of how a yeast cell responds to the metabolic load of producing recombinant proteins will allow us to identify host strains that have improved yield properties and enable the synthesis of more challenging antigens that cannot be produced in other systems. Yeasts therefore have the potential to become important host organisms for the production of recombinant antigens that can be used in the manufacture of subunit vaccines or in new vaccine development.</p></section></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Recombinant protein subunit vaccines</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?</title></titleInfo><name type="personal"><namePart type="given">Roslyn M.</namePart><namePart type="family">Bill</namePart><affiliation>School of Life and Health Sciences, Aston University, Birmingham, UK</affiliation><affiliation>Roslyn M. Bill, School of Life and Health Sciences, Aston University, Aston Triangle, B4 7ET Birmingham, UK.E‐mail:</affiliation><affiliation>E-mail: r.m.bill@aston.ac.uk</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2015-03</dateIssued><dateCreated encoding="w3cdtf">2014-11-05</dateCreated><dateCaptured encoding="w3cdtf">2014-06-10</dateCaptured><dateValid encoding="w3cdtf">2014-10-18</dateValid><copyrightDate encoding="w3cdtf">2015</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract>Objectives: Recombinant protein subunit vaccines are formulated using protein antigens that have been synthesized in heterologous host cells. Several host cells are available for this purpose, ranging from Escherichia coli to mammalian cell lines. This article highlights the benefits of using yeast as the recombinant host. Key findings: The yeast species, Saccharomyces cerevisiae and Pichia pastoris, have been used to optimize the functional yields of potential antigens for the development of subunit vaccines against a wide range of diseases caused by bacteria and viruses. Saccharomyces cerevisiae has also been used in the manufacture of 11 approved vaccines against hepatitis B virus and one against human papillomavirus; in both cases, the recombinant protein forms highly immunogenic virus‐like particles. Summary: Advances in our understanding of how a yeast cell responds to the metabolic load of producing recombinant proteins will allow us to identify host strains that have improved yield properties and enable the synthesis of more challenging antigens that cannot be produced in other systems. Yeasts therefore have the potential to become important host organisms for the production of recombinant antigens that can be used in the manufacture of subunit vaccines or in new vaccine development.</abstract><subject><genre>keywords</genre><topic>Pichia pastoris</topic><topic>recombinant antigen</topic><topic>Saccharomyces cerevisiae</topic><topic>yeast</topic></subject><relatedItem type="host"><titleInfo><title>Journal of Pharmacy and Pharmacology</title></titleInfo><titleInfo type="abbreviated"><title>J Pharm Pharmacol</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>REVIEW</topic><topic>REVIEW</topic></subject><identifier type="ISSN">0022-3573</identifier><identifier type="eISSN">2042-7158</identifier><identifier type="DOI">10.1111/(ISSN)2042-7158</identifier><identifier type="PublisherID">JPHP</identifier><part><date>2015</date><detail type="title"><title>Enhancing Vaccine Design Strategies. Guest Editors: Yvonne Perrie, Helen R. Griffiths and David Jones</title></detail><detail type="volume"><caption>vol.</caption><number>67</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>319</start><end>328</end><total>10</total></extent></part></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0001"><titleInfo><title>Child and adolescent immunizations: selected review of recent US recommendations and literature</title></titleInfo><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Kao</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kao CM et al. Child and adolescent immunizations: selected review of recent US recommendations and literature. Curr Opin Pediatr 2014; 26: 383–395.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>383</start><end>395</end></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Pediatr</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>383</start><end>395</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0002"><titleInfo><title>Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines</title></titleInfo><name type="personal"><namePart type="given">S</namePart><namePart type="family">Liljeqvist</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Stahl</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liljeqvist S, Stahl S. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. J Biotechnol 1999; 73: 1–33.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>1</start><end>33</end></extent></part><relatedItem type="host"><titleInfo><title>J Biotechnol</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>73</number></detail><extent unit="pages"><start>1</start><end>33</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0003"><titleInfo><title>Vaccine adjuvants: putting innate immunity to work</title></titleInfo><name type="personal"><namePart type="given">RL</namePart><namePart type="family">Coffman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Coffman RL et al. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33: 492–503.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>492</start><end>503</end></extent></part><relatedItem type="host"><titleInfo><title>Immunity</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>492</start><end>503</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0004"><titleInfo><title>Vaccines: past, present and future</title></titleInfo><name type="personal"><namePart type="given">SA</namePart><namePart type="family">Plotkin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Plotkin SA. Vaccines: past, present and future. Nat Med 2005; 11: S5–S11.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>S5</start><end>S11</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Med</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>S5</start><end>S11</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0005"><titleInfo><title>Playing catch‐up with Escherichia coli: using yeast to increase success rates in recombinant protein production experiments</title></titleInfo><name type="personal"><namePart type="given">RM</namePart><namePart type="family">Bill</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bill RM. Playing catch‐up with Escherichia coli: using yeast to increase success rates in recombinant protein production experiments. Front Microbiol 2014; 5: 85.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>85</start></extent></part><relatedItem type="host"><titleInfo><title>Front Microbiol</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>85</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0006"><titleInfo><title>Phase 1/2a study of the malaria vaccine candidate apical membrane antigen‐1 (AMA‐1) administered in adjuvant system AS01B or AS02A</title></titleInfo><name type="personal"><namePart type="given">MD</namePart><namePart type="family">Spring</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Spring MD et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen‐1 (AMA‐1) administered in adjuvant system AS01B or AS02A. PLoS ONE 2009; 4: e5254.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>e5254</start></extent></part><relatedItem type="host"><titleInfo><title>PLoS ONE</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>e5254</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0007"><titleInfo><title>Virus‐like particles in vaccine development</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Roldao</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Roldao A et al. Virus‐like particles in vaccine development. Expert Rev Vaccines 2010; 9: 1149–1176.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>1149</start><end>1176</end></extent></part><relatedItem type="host"><titleInfo><title>Expert Rev Vaccines</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>1149</start><end>1176</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0009"><titleInfo><title>Construction of biologically functional bacterial plasmids in vitro</title></titleInfo><name type="personal"><namePart type="given">SN</namePart><namePart type="family">Cohen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cohen SN et al. Construction of biologically functional bacterial plasmids in vitro. Proc Natl Acad Sci U S A 1973; 70: 3240–3244.</note><part><date>1973</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>3240</start><end>3244</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci U S A</title></titleInfo><part><date>1973</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>3240</start><end>3244</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0010"><titleInfo><title>Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Itakura</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Itakura K et al. Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin. Science 1977; 198: 1056–1063.</note><part><date>1977</date><detail type="volume"><caption>vol.</caption><number>198</number></detail><extent unit="pages"><start>1056</start><end>1063</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>1977</date><detail type="volume"><caption>vol.</caption><number>198</number></detail><extent unit="pages"><start>1056</start><end>1063</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0011"><titleInfo><title>Expression in Escherichia coli of chemically synthesized genes for human insulin</title></titleInfo><name type="personal"><namePart type="given">DV</namePart><namePart type="family">Goeddel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goeddel DV et al. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci U S A 1979; 76: 106–110.</note><part><date>1979</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>106</start><end>110</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci U S A</title></titleInfo><part><date>1979</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><extent unit="pages"><start>106</start><end>110</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0012"><titleInfo><title>Market watch: sales of biologics to show robust growth through to 2013</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Goodman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goodman M. Market watch: sales of biologics to show robust growth through to 2013. Nat Rev Drug Discov 2009; 8: 837.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>837</start></extent></part><relatedItem type="host"><titleInfo><title>Nat Rev Drug Discov</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>837</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0013"><titleInfo><title>Microbial factories for recombinant pharmaceuticals</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Ferrer‐Miralles</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ferrer‐Miralles N et al. Microbial factories for recombinant pharmaceuticals. Microb Cell Fact 2009; 8: 17.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>17</start></extent></part><relatedItem type="host"><titleInfo><title>Microb Cell Fact</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>17</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0014"><titleInfo><title>Mammalian cell protein expression for biopharmaceutical production</title></titleInfo><name type="personal"><namePart type="given">J</namePart><namePart type="family">Zhu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhu J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 2012; 30: 1158–1170.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>1158</start><end>1170</end></extent></part><relatedItem type="host"><titleInfo><title>Biotechnol Adv</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>1158</start><end>1170</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0015"><titleInfo><title>Recombinant protein production in yeasts</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Mattanovich</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mattanovich D et al. Recombinant protein production in yeasts. Methods Mol Biol 2012; 824: 329–358.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>824</number></detail><extent unit="pages"><start>329</start><end>358</end></extent></part><relatedItem type="host"><titleInfo><title>Methods Mol Biol</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>824</number></detail><extent unit="pages"><start>329</start><end>358</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0016"><titleInfo><title>Synthesis and assembly of hepatitis B virus surface antigen particles in yeast</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Valenzuela</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Valenzuela P et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982; 298: 347–350.</note><part><date>1982</date><detail type="volume"><caption>vol.</caption><number>298</number></detail><extent unit="pages"><start>347</start><end>350</end></extent></part><relatedItem type="host"><titleInfo><title>Nature</title></titleInfo><part><date>1982</date><detail type="volume"><caption>vol.</caption><number>298</number></detail><extent unit="pages"><start>347</start><end>350</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0017"><titleInfo><title>The Lyme vaccine: a cautionary tale</title></titleInfo><name type="personal"><namePart type="given">LE</namePart><namePart type="family">Nigrovic</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KM</namePart><namePart type="family">Thompson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nigrovic LE, Thompson KM. The Lyme vaccine: a cautionary tale. Epidemiol Infect 2007; 135: 1–8.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>135</number></detail><extent unit="pages"><start>1</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Epidemiol Infect</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>135</number></detail><extent unit="pages"><start>1</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0018"><titleInfo><title>The cost effectiveness of vaccinating against Lyme disease</title></titleInfo><name type="personal"><namePart type="given">MI</namePart><namePart type="family">Meltzer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Meltzer MI et al. The cost effectiveness of vaccinating against Lyme disease. Emerg Infect Dis 1999; 5: 321–328.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>321</start><end>328</end></extent></part><relatedItem type="host"><titleInfo><title>Emerg Infect Dis</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>321</start><end>328</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0019"><titleInfo><title>Anthrax sub‐unit vaccine: the structural consequences of binding rPA83 to Alhydrogel(R)</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Soliakov</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Soliakov A et al. Anthrax sub‐unit vaccine: the structural consequences of binding rPA83 to Alhydrogel(R). Eur J Pharm Biopharm 2012; 80: 25–32.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>25</start><end>32</end></extent></part><relatedItem type="host"><titleInfo><title>Eur J Pharm Biopharm</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>80</number></detail><extent unit="pages"><start>25</start><end>32</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0020"><titleInfo><title>Protection conferred by a fully recombinant sub‐unit vaccine against Yersinia pestis in male and female mice of four inbred strains</title></titleInfo><name type="personal"><namePart type="given">SM</namePart><namePart type="family">Jones</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jones SM et al. Protection conferred by a fully recombinant sub‐unit vaccine against Yersinia pestis in male and female mice of four inbred strains. Vaccine 2000; 19: 358–366.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>358</start><end>366</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>358</start><end>366</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0021"><titleInfo><title>Cloning, expression and evaluation of a recombinant sub‐unit vaccine against Clostridium botulinum type F toxin</title></titleInfo><name type="personal"><namePart type="given">JL</namePart><namePart type="family">Holley</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Holley JL et al. Cloning, expression and evaluation of a recombinant sub‐unit vaccine against Clostridium botulinum type F toxin. Vaccine 2000; 19: 288–297.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>288</start><end>297</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>288</start><end>297</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0022"><titleInfo><title>Vaccine development against infection with Helicobacter pylori</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Kleanthous</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kleanthous H et al. Vaccine development against infection with Helicobacter pylori. Br Med Bull 1998; 54: 229–241.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>229</start><end>241</end></extent></part><relatedItem type="host"><titleInfo><title>Br Med Bull</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>54</number></detail><extent unit="pages"><start>229</start><end>241</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0023"><titleInfo><title>Sub‐unit vaccine against S. aureus‐mediated infections: set‐up of nano‐sized polymeric adjuvant</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Colonna</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Colonna C et al. Sub‐unit vaccine against S. aureus‐mediated infections: set‐up of nano‐sized polymeric adjuvant. Int J Pharm 2013; 452: 390–401.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>452</number></detail><extent unit="pages"><start>390</start><end>401</end></extent></part><relatedItem type="host"><titleInfo><title>Int J Pharm</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>452</number></detail><extent unit="pages"><start>390</start><end>401</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0024"><titleInfo><title>Development and pre‐clinical assessment of a 73 kD chimeric fusion protein as a defined sub‐unit vaccine for leprosy</title></titleInfo><name type="personal"><namePart type="given">MS</namePart><namePart type="family">Duthie</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Duthie MS et al. Development and pre‐clinical assessment of a 73 kD chimeric fusion protein as a defined sub‐unit vaccine for leprosy. Vaccine 2013; 31: 813–819.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>813</start><end>819</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>813</start><end>819</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0025"><titleInfo><title>Plasmodium vivax apical membrane antigen‐1: comparative recognition of different domains by antibodies induced during natural human infection</title></titleInfo><name type="personal"><namePart type="given">BC</namePart><namePart type="family">Mufalo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mufalo BC et al. Plasmodium vivax apical membrane antigen‐1: comparative recognition of different domains by antibodies induced during natural human infection. Microbes Infect 2008; 10: 1266–1273.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>1266</start><end>1273</end></extent></part><relatedItem type="host"><titleInfo><title>Microbes Infect</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>1266</start><end>1273</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0026"><titleInfo><title>Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques</title></titleInfo><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Vanloubbeeck</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vanloubbeeck Y et al. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques. Vaccine 2013; 31: 6216–6224.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>6216</start><end>6224</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>6216</start><end>6224</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0027"><titleInfo><title>Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat‐6</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Weinrich Olsen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Weinrich Olsen A et al. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat‐6. Infect Immun 2001; 69: 2773–2778.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>2773</start><end>2778</end></extent></part><relatedItem type="host"><titleInfo><title>Infect Immun</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>2773</start><end>2778</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0028"><titleInfo><title>Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Ramirez</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ramirez R et al. Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design. Virus Genes 2014; 49: 185–195.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>185</start><end>195</end></extent></part><relatedItem type="host"><titleInfo><title>Virus Genes</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><extent unit="pages"><start>185</start><end>195</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0029"><titleInfo><title>Expression and immunogenic analysis of recombinant polypeptides derived from capsid protein VP1 for developing subunit vaccine material against hepatitis A virus</title></titleInfo><name type="personal"><namePart type="given">KO</namePart><namePart type="family">Jang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jang KO et al. Expression and immunogenic analysis of recombinant polypeptides derived from capsid protein VP1 for developing subunit vaccine material against hepatitis A virus. Protein Expr Purif 2014; 100C: 1–9.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>100C</number></detail><extent unit="pages"><start>1</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Protein Expr Purif</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>100C</number></detail><extent unit="pages"><start>1</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0030"><titleInfo><title>High level expression, purification and characterization of recombinant CCR5 as a vaccine candidate against HIV</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Wu</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wu K et al. High level expression, purification and characterization of recombinant CCR5 as a vaccine candidate against HIV. Protein Expr Purif 2013; 89: 124–130.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>124</start><end>130</end></extent></part><relatedItem type="host"><titleInfo><title>Protein Expr Purif</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>124</start><end>130</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0031"><titleInfo><title>Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates</title></titleInfo><name type="personal"><namePart type="given">X</namePart><namePart type="family">Wen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wen X et al. Construction and characterization of human rotavirus recombinant VP8* subunit parenteral vaccine candidates. Vaccine 2012; 30: 6121–6126.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>6121</start><end>6126</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>6121</start><end>6126</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0032"><titleInfo><title>A novel bipolar mode of attachment to aluminium‐containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Dagouassat</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dagouassat N et al. A novel bipolar mode of attachment to aluminium‐containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine. Vaccine 2001; 19: 4143–4152.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>4143</start><end>4152</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>4143</start><end>4152</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0033"><titleInfo><title>Safety and immunogenicity of a recombinant hemagglutinin influenza‐flagellin fusion vaccine (VAX125) in healthy young adults</title></titleInfo><name type="personal"><namePart type="given">JJ</namePart><namePart type="family">Treanor</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Treanor JJ et al. Safety and immunogenicity of a recombinant hemagglutinin influenza‐flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine 2010; 28: 8268–8274.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>8268</start><end>8274</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>8268</start><end>8274</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0034"><titleInfo><title>Cloning, expression and characterization of recombinant exotoxin A‐flagellin fusion protein as a new vaccine candidate against Pseudomonas aeruginosa infections</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Tanomand</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tanomand A et al. Cloning, expression and characterization of recombinant exotoxin A‐flagellin fusion protein as a new vaccine candidate against Pseudomonas aeruginosa infections. Iran Biomed J 2013; 17: 1–7.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>1</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Iran Biomed J</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>1</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0035"><titleInfo><title>Refolding of the recombinant protein Sm29, a step toward the production of the vaccine candidate against schistosomiasis</title></titleInfo><name type="personal"><namePart type="given">RM</namePart><namePart type="family">Chura‐Chambi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chura‐Chambi RM et al. Refolding of the recombinant protein Sm29, a step toward the production of the vaccine candidate against schistosomiasis. J Biotechnol 2013; 168: 511–519.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>168</number></detail><extent unit="pages"><start>511</start><end>519</end></extent></part><relatedItem type="host"><titleInfo><title>J Biotechnol</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>168</number></detail><extent unit="pages"><start>511</start><end>519</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0036"><titleInfo><title>Towards universal systems for recombinant gene expression</title></titleInfo><name type="personal"><namePart type="given">HP</namePart><namePart type="family">Sørensen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Sørensen HP. Towards universal systems for recombinant gene expression. Microb Cell Fact 2010; 9: 27.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>27</start></extent></part><relatedItem type="host"><titleInfo><title>Microb Cell Fact</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>27</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0037"><titleInfo><title>Recent advances in mammalian protein production</title></titleInfo><name type="personal"><namePart type="given">AD</namePart><namePart type="family">Bandaranayake</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SC</namePart><namePart type="family">Almo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bandaranayake AD, Almo SC. Recent advances in mammalian protein production. FEBS Lett 2013; 588: 253–260.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>588</number></detail><extent unit="pages"><start>253</start><end>260</end></extent></part><relatedItem type="host"><titleInfo><title>FEBS Lett</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>588</number></detail><extent unit="pages"><start>253</start><end>260</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0038"><titleInfo><title>Recent advances in recombinant protein production: BAC‐based expression vectors, the bigger the better</title></titleInfo><name type="personal"><namePart type="given">R</namePart><namePart type="family">Kunert</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Casanova</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kunert R, Casanova E. Recent advances in recombinant protein production: BAC‐based expression vectors, the bigger the better. Bioengineered 2013; 4: 258–261.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>258</start><end>261</end></extent></part><relatedItem type="host"><titleInfo><title>Bioengineered</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>258</start><end>261</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0039"><titleInfo><title>Comparison of folding rates of homologous prokaryotic and eukaryotic proteins</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Widmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Christen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Widmann M, Christen P. Comparison of folding rates of homologous prokaryotic and eukaryotic proteins. J Biol Chem 2000; 275: 18619–18622.</note><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>275</number></detail><extent unit="pages"><start>18619</start><end>18622</end></extent></part><relatedItem type="host"><titleInfo><title>J Biol Chem</title></titleInfo><part><date>2000</date><detail type="volume"><caption>vol.</caption><number>275</number></detail><extent unit="pages"><start>18619</start><end>18622</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0040"><titleInfo><title>Safety and immunogenicity of palivizumab (Synagis) administered for two seasons</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Null Jr</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Null D Jr et al. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J 2005; 24: 1021–1023.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>1021</start><end>1023</end></extent></part><relatedItem type="host"><titleInfo><title>Pediatr Infect Dis J</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>1021</start><end>1023</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0041"><titleInfo><title>Glycoprotein‐D‐adjuvant vaccine to prevent genital herpes</title></titleInfo><name type="personal"><namePart type="given">LR</namePart><namePart type="family">Stanberry</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Stanberry LR et al. Glycoprotein‐D‐adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347: 1652–1661.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>347</number></detail><extent unit="pages"><start>1652</start><end>1661</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>347</number></detail><extent unit="pages"><start>1652</start><end>1661</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0042"><titleInfo><title>Easy expression of the C‐terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi‐cistronic baculovirus system</title></titleInfo><name type="personal"><namePart type="given">OB</namePart><namePart type="family">Villaflores</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Villaflores OB et al. Easy expression of the C‐terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi‐cistronic baculovirus system. J Virol Methods 2013; 189: 58–64.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>189</number></detail><extent unit="pages"><start>58</start><end>64</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol Methods</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>189</number></detail><extent unit="pages"><start>58</start><end>64</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0043"><titleInfo><title>Comparative testing of six antigen‐based malaria vaccine candidates directed toward merozoite‐stage Plasmodium falciparum</title></titleInfo><name type="personal"><namePart type="given">DE</namePart><namePart type="family">Arnot</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Arnot DE et al. Comparative testing of six antigen‐based malaria vaccine candidates directed toward merozoite‐stage Plasmodium falciparum. Clin Vaccine Immunol 2008; 15: 1345–1355.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>1345</start><end>1355</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Vaccine Immunol</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>15</number></detail><extent unit="pages"><start>1345</start><end>1355</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0044"><titleInfo><title>Recombinant glycoprotein based vaccine for Chandipura virus infection</title></titleInfo><name type="personal"><namePart type="given">CH</namePart><namePart type="family">Venkateswarlu</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">VA</namePart><namePart type="family">Arankalle</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Venkateswarlu CH, Arankalle VA. Recombinant glycoprotein based vaccine for Chandipura virus infection. Vaccine 2009; 27: 2845–2850.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>2845</start><end>2850</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>2845</start><end>2850</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0045"><titleInfo><title>Purification and characterization of a recombinant hepatitis E protein vaccine candidate by liquid chromatography‐mass spectrometry</title></titleInfo><name type="personal"><namePart type="given">CP</namePart><namePart type="family">McAtee</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">McAtee CP et al. Purification and characterization of a recombinant hepatitis E protein vaccine candidate by liquid chromatography‐mass spectrometry. J Chromatogr B Biomed Appl 1996; 685: 91–104.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>685</number></detail><extent unit="pages"><start>91</start><end>104</end></extent></part><relatedItem type="host"><titleInfo><title>J Chromatogr B Biomed Appl</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>685</number></detail><extent unit="pages"><start>91</start><end>104</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0046"><titleInfo><title>Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine</title></titleInfo><name type="personal"><namePart type="given">YP</namePart><namePart type="family">Shi</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Shi YP et al. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc Natl Acad Sci U S A 1999; 96: 1615–1620.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>1615</start><end>1620</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci U S A</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>96</number></detail><extent unit="pages"><start>1615</start><end>1620</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0047"><titleInfo><title>A recombinant baculovirus‐expressed S glycoprotein vaccine elicits high titers of SARS‐associated coronavirus (SARS‐CoV) neutralizing antibodies in mice</title></titleInfo><name type="personal"><namePart type="given">Z</namePart><namePart type="family">Zhou</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhou Z et al. A recombinant baculovirus‐expressed S glycoprotein vaccine elicits high titers of SARS‐associated coronavirus (SARS‐CoV) neutralizing antibodies in mice. Vaccine 2006; 24: 3624–3631.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>3624</start><end>3631</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>3624</start><end>3631</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0048"><titleInfo><title>A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF + cells</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Bonafe</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bonafe N et al. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF + cells. Vaccine 2009; 27: 213–222.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>213</start><end>222</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>213</start><end>222</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0049"><titleInfo><title>The production of recombinant pharmaceutical proteins in plants</title></titleInfo><name type="personal"><namePart type="given">JK</namePart><namePart type="family">Ma</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ma JK et al. The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet 2003; 4: 794–805.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>794</start><end>805</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Rev Genet</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>4</number></detail><extent unit="pages"><start>794</start><end>805</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0050"><titleInfo><title>Plant‐based vaccines</title></titleInfo><name type="personal"><namePart type="given">SJ</namePart><namePart type="family">Streatfield</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JA</namePart><namePart type="family">Howard</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Streatfield SJ, Howard JA. Plant‐based vaccines. Int J Parasitol 2003; 33: 479–493.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>479</start><end>493</end></extent></part><relatedItem type="host"><titleInfo><title>Int J Parasitol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>33</number></detail><extent unit="pages"><start>479</start><end>493</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0051"><titleInfo><title>Plant‐derived measles virus hemagglutinin protein induces neutralizing antibodies in mice</title></titleInfo><name type="personal"><namePart type="given">Z</namePart><namePart type="family">Huang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Huang Z et al. Plant‐derived measles virus hemagglutinin protein induces neutralizing antibodies in mice. Vaccine 2001; 19: 2163–2171.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>2163</start><end>2171</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>2163</start><end>2171</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0052"><titleInfo><title>Genome sequence of the recombinant protein production host Pichia pastoris</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">De Schutter</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">De Schutter K et al. Genome sequence of the recombinant protein production host Pichia pastoris. Nat Biotechnol 2009; 27: 561–566.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>561</start><end>566</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Biotechnol</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><extent unit="pages"><start>561</start><end>566</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0053"><titleInfo><title>Life with 6000 genes</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Goffeau</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Goffeau A et al. Life with 6000 genes. Science 1996; 274: 546–567.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>274</number></detail><extent unit="pages"><start>546</start><end>567</end></extent></part><relatedItem type="host"><titleInfo><title>Science</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>274</number></detail><extent unit="pages"><start>546</start><end>567</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0054"><titleInfo><title>Production of recombinant proteins and metabolites in yeasts: when are these systems better than bacterial production systems?</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Porro</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Porro D et al. Production of recombinant proteins and metabolites in yeasts: when are these systems better than bacterial production systems? Appl Microbiol Biotechnol 2011; 89: 939–948.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>939</start><end>948</end></extent></part><relatedItem type="host"><titleInfo><title>Appl Microbiol Biotechnol</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>89</number></detail><extent unit="pages"><start>939</start><end>948</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0055"><titleInfo><title>A recombinant 63‐kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection</title></titleInfo><name type="personal"><namePart type="given">RW</namePart><namePart type="family">Hepler</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Hepler RW et al. A recombinant 63‐kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection. Vaccine 2006; 24: 1501–1514.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>1501</start><end>1514</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>24</number></detail><extent unit="pages"><start>1501</start><end>1514</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0056"><titleInfo><title>Expression of tetanus toxin fragment C in yeast: gene synthesis is required to eliminate fortuitous polyadenylation sites in AT‐rich DNA</title></titleInfo><name type="personal"><namePart type="given">MA</namePart><namePart type="family">Romanos</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Romanos MA et al. Expression of tetanus toxin fragment C in yeast: gene synthesis is required to eliminate fortuitous polyadenylation sites in AT‐rich DNA. Nucleic Acids Res 1991; 19: 1461–1467.</note><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>1461</start><end>1467</end></extent></part><relatedItem type="host"><titleInfo><title>Nucleic Acids Res</title></titleInfo><part><date>1991</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><extent unit="pages"><start>1461</start><end>1467</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0057"><titleInfo><title>Expression and purification of an immunogenic dengue virus epitope using a synthetic consensus sequence of envelope domain III and Saccharomyces cerevisiae</title></titleInfo><name type="personal"><namePart type="given">NL</namePart><namePart type="family">Nguyen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Nguyen NL et al. Expression and purification of an immunogenic dengue virus epitope using a synthetic consensus sequence of envelope domain III and Saccharomyces cerevisiae. Protein Expr Purif 2013; 88: 235–242.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>88</number></detail><extent unit="pages"><start>235</start><end>242</end></extent></part><relatedItem type="host"><titleInfo><title>Protein Expr Purif</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>88</number></detail><extent unit="pages"><start>235</start><end>242</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0058"><titleInfo><title>Production of hantavirus Puumala nucleocapsid protein in Saccharomyces cerevisiae for vaccine and diagnostics</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Antoniukas</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Antoniukas L et al. Production of hantavirus Puumala nucleocapsid protein in Saccharomyces cerevisiae for vaccine and diagnostics. J Biotechnol 2006; 124: 347–362.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>124</number></detail><extent unit="pages"><start>347</start><end>362</end></extent></part><relatedItem type="host"><titleInfo><title>J Biotechnol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>124</number></detail><extent unit="pages"><start>347</start><end>362</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0059"><titleInfo><title>Trans‐packaging of human immunodeficiency virus type 1 genome into Gag virus‐like particles in Saccharomyces cerevisiae</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Tomo</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tomo N et al. Trans‐packaging of human immunodeficiency virus type 1 genome into Gag virus‐like particles in Saccharomyces cerevisiae. Microb Cell Fact 2013; 12: 28.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>28</start></extent></part><relatedItem type="host"><titleInfo><title>Microb Cell Fact</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>28</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0060"><titleInfo><title>Recombinant outer‐surface protein A (des‐Cys1‐OspA) from the Lyme disease spirochete Borrelia burgdorferi: high production levels in Saccharomyces cerevisiae yeast cultures</title></titleInfo><name type="personal"><namePart type="given">O</namePart><namePart type="family">Mendoza‐Vega</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Mendoza‐Vega O et al. Recombinant outer‐surface protein A (des‐Cys1‐OspA) from the Lyme disease spirochete Borrelia burgdorferi: high production levels in Saccharomyces cerevisiae yeast cultures. Appl Microbiol Biotechnol 1996; 44: 624–628.</note><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>624</start><end>628</end></extent></part><relatedItem type="host"><titleInfo><title>Appl Microbiol Biotechnol</title></titleInfo><part><date>1996</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>624</start><end>628</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0061"><titleInfo><title>Malaria vaccines: focus on adenovirus based vectors</title></titleInfo><name type="personal"><namePart type="given">NJ</namePart><namePart type="family">Schuldt</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Amalfitano</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Schuldt NJ, Amalfitano A. Malaria vaccines: focus on adenovirus based vectors. Vaccine 2012; 30: 5191–5198.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>5191</start><end>5198</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>5191</start><end>5198</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0062"><titleInfo><title>Saccharomyces cerevisiae‐secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission‐blocking antibodies in mice</title></titleInfo><name type="personal"><namePart type="given">MM</namePart><namePart type="family">Gozar</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gozar MM et al. Saccharomyces cerevisiae‐secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission‐blocking antibodies in mice. Infect Immun 1998; 66: 59–64.</note><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>59</start><end>64</end></extent></part><relatedItem type="host"><titleInfo><title>Infect Immun</title></titleInfo><part><date>1998</date><detail type="volume"><caption>vol.</caption><number>66</number></detail><extent unit="pages"><start>59</start><end>64</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0063"><titleInfo><title>Immunogenic, non‐infectious polio subviral particles synthesized in Saccharomyces cerevisiae</title></titleInfo><name type="personal"><namePart type="given">B</namePart><namePart type="family">Rombaut</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JP</namePart><namePart type="family">Jore</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rombaut B, Jore JP. Immunogenic, non‐infectious polio subviral particles synthesized in Saccharomyces cerevisiae. J Gen Virol 1997; 78(Pt 8): 1829–1832.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><detail type="issue"><caption>no.</caption><number>Pt 8</number></detail><extent unit="pages"><start>1829</start><end>1832</end></extent></part><relatedItem type="host"><titleInfo><title>J Gen Virol</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>78</number></detail><detail type="issue"><caption>no.</caption><number>Pt 8</number></detail><extent unit="pages"><start>1829</start><end>1832</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0064"><titleInfo><title>Characterization of rabies glycoprotein expressed in yeast</title></titleInfo><name type="personal"><namePart type="given">SR</namePart><namePart type="family">Klepfer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Klepfer SR et al. Characterization of rabies glycoprotein expressed in yeast. Arch Virol 1993; 128: 269–286.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>128</number></detail><extent unit="pages"><start>269</start><end>286</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Virol</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>128</number></detail><extent unit="pages"><start>269</start><end>286</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0065"><titleInfo><title>Molecular and process design for rotavirus‐like particle production in Saccharomyces cerevisiae</title></titleInfo><name type="personal"><namePart type="given">WA</namePart><namePart type="family">Rodriguez‐Limas</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rodriguez‐Limas WA et al. Molecular and process design for rotavirus‐like particle production in Saccharomyces cerevisiae. Microb Cell Fact 2011; 10: 33.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>33</start></extent></part><relatedItem type="host"><titleInfo><title>Microb Cell Fact</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>33</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0066"><titleInfo><title>Yeast expressed foldable quadrivalent Abeta15 elicited strong immune response against Abeta without Abeta‐specific T cell response in wild C57BL/6 mice</title></titleInfo><name type="personal"><namePart type="given">L</namePart><namePart type="family">Tan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Tan L et al. Yeast expressed foldable quadrivalent Abeta15 elicited strong immune response against Abeta without Abeta‐specific T cell response in wild C57BL/6 mice. Hum Vaccin Immunother. 2012; 8: 1090–1098.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>1090</start><end>1098</end></extent></part><relatedItem type="host"><titleInfo><title>Hum Vaccin Immunother.</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>1090</start><end>1098</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0067"><titleInfo><title>Immunization with an engineered mutant trans‐sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate</title></titleInfo><name type="personal"><namePart type="given">GH</namePart><namePart type="family">Fontanella</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Fontanella GH et al. Immunization with an engineered mutant trans‐sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate. Vaccine 2008; 26: 2322–2334.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>2322</start><end>2334</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>2322</start><end>2334</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0068"><titleInfo><title>Optimization of conditions for secretion of dengue virus type 2 envelope domain III using Pichia pastoris</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Batra</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Batra G et al. Optimization of conditions for secretion of dengue virus type 2 envelope domain III using Pichia pastoris. J Biosci Bioeng 2010; 110: 408–414.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>408</start><end>414</end></extent></part><relatedItem type="host"><titleInfo><title>J Biosci Bioeng</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>110</number></detail><extent unit="pages"><start>408</start><end>414</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0069"><titleInfo><title>Expression, purification, and immunogenic characterization of Epstein–Barr virus recombinant EBNA1 protein in Pichia pastoris</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wang M et al. Expression, purification, and immunogenic characterization of Epstein–Barr virus recombinant EBNA1 protein in Pichia pastoris. Appl Microbiol Biotechnol 2013; 97: 6251–6262.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>97</number></detail><extent unit="pages"><start>6251</start><end>6262</end></extent></part><relatedItem type="host"><titleInfo><title>Appl Microbiol Biotechnol</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>97</number></detail><extent unit="pages"><start>6251</start><end>6262</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0070"><titleInfo><title>Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Wang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Wang M et al. Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice. Biochem Biophys Res Commun 2013; 430: 387–393.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>430</number></detail><extent unit="pages"><start>387</start><end>393</end></extent></part><relatedItem type="host"><titleInfo><title>Biochem Biophys Res Commun</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>430</number></detail><extent unit="pages"><start>387</start><end>393</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0071"><titleInfo><title>Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine</title></titleInfo><name type="personal"><namePart type="given">AAO</namePart><namePart type="family">Riordan</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Riordan AAO et al. Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine. Vaccine 2012; 30: 3876–3884.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>3876</start><end>3884</end></extent></part><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>30</number></detail><extent unit="pages"><start>3876</start><end>3884</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0072"><titleInfo><title>Purification of hepatitis B surface antigen virus‐like particles from recombinant Pichia pastoris and in vivo analysis of their immunogenic properties</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Gurramkonda</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Gurramkonda C et al. Purification of hepatitis B surface antigen virus‐like particles from recombinant Pichia pastoris and in vivo analysis of their immunogenic properties. J Chromatogr B Analyt Technol Biomed Life Sci 2013; 940: 104–111.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>940</number></detail><extent unit="pages"><start>104</start><end>111</end></extent></part><relatedItem type="host"><titleInfo><title>J Chromatogr B Analyt Technol Biomed Life Sci</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>940</number></detail><extent unit="pages"><start>104</start><end>111</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0073"><titleInfo><title>Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast</title></titleInfo><name type="personal"><namePart type="given">W</namePart><namePart type="family">Cai</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cai W et al. Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast. Antiviral Res 2010; 88: 80–85.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>88</number></detail><extent unit="pages"><start>80</start><end>85</end></extent></part><relatedItem type="host"><titleInfo><title>Antiviral Res</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>88</number></detail><extent unit="pages"><start>80</start><end>85</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0074"><titleInfo><title>Optimization and revisions of the production process of the Necator americanus glutathione S‐transferase 1 (Na‐GST‐1), the lead hookworm vaccine recombinant protein candidate</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Curti</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Curti E et al. Optimization and revisions of the production process of the Necator americanus glutathione S‐transferase 1 (Na‐GST‐1), the lead hookworm vaccine recombinant protein candidate. Hum Vaccin Immunother 2014; 10: 1914–1925.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>1914</start><end>1925</end></extent></part><relatedItem type="host"><titleInfo><title>Hum Vaccin Immunother</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>1914</start><end>1925</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0075"><titleInfo><title>Expression and characterization of Gag protein of HIV‐1(CN) in Pichia pastoris</title></titleInfo><name type="personal"><namePart type="given">WZ</namePart><namePart type="family">Jiang</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jiang WZ et al. Expression and characterization of Gag protein of HIV‐1(CN) in Pichia pastoris. J Virol Methods 2005; 123: 35–40.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>35</start><end>40</end></extent></part><relatedItem type="host"><titleInfo><title>J Virol Methods</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>123</number></detail><extent unit="pages"><start>35</start><end>40</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0076"><titleInfo><title>Production of L1 protein from different types of HPV in Pichia pastoris using an integrative vector</title></titleInfo><name type="personal"><namePart type="given">EC</namePart><namePart type="family">Coimbra</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Coimbra EC et al. Production of L1 protein from different types of HPV in Pichia pastoris using an integrative vector. Braz J Med Biol Res 2011; 44: 1209–1214.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1209</start><end>1214</end></extent></part><relatedItem type="host"><titleInfo><title>Braz J Med Biol Res</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>44</number></detail><extent unit="pages"><start>1209</start><end>1214</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0077"><titleInfo><title>Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP‐2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis</title></titleInfo><name type="personal"><namePart type="given">E</namePart><namePart type="family">Curti</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Curti E et al. Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP‐2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis. Hum Vaccin Immunother 2013; 9: 2342–2350.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>2342</start><end>2350</end></extent></part><relatedItem type="host"><titleInfo><title>Hum Vaccin Immunother</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>2342</start><end>2350</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0078"><titleInfo><title>Evaluation of antibody response in mice against avian influenza A (H5N1) strain neuraminidase expressed in yeast Pichia pastoris</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Subathra</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Subathra M et al. Evaluation of antibody response in mice against avian influenza A (H5N1) strain neuraminidase expressed in yeast Pichia pastoris. J Biosci 2014; 39: 443–451.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>443</start><end>451</end></extent></part><relatedItem type="host"><titleInfo><title>J Biosci</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>39</number></detail><extent unit="pages"><start>443</start><end>451</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0079"><titleInfo><title>A simple Pichia pastoris fermentation and downstream processing strategy for making recombinant pandemic Swine Origin Influenza a virus Hemagglutinin protein</title></titleInfo><name type="personal"><namePart type="given">TN</namePart><namePart type="family">Athmaram</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Athmaram TN et al. A simple Pichia pastoris fermentation and downstream processing strategy for making recombinant pandemic Swine Origin Influenza a virus Hemagglutinin protein. J Ind Microbiol Biotechnol 2013; 40: 245–255.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>245</start><end>255</end></extent></part><relatedItem type="host"><titleInfo><title>J Ind Microbiol Biotechnol</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>245</start><end>255</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0080"><titleInfo><title>Protective immunity of Pichia pastoris‐expressed recombinant envelope protein of Japanese encephalitis virus</title></titleInfo><name type="personal"><namePart type="given">WT</namePart><namePart type="family">Kwon</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kwon WT et al. Protective immunity of Pichia pastoris‐expressed recombinant envelope protein of Japanese encephalitis virus. J Microbiol Biotechnol 2012; 22: 1580–1587.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1580</start><end>1587</end></extent></part><relatedItem type="host"><titleInfo><title>J Microbiol Biotechnol</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>1580</start><end>1587</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0081"><titleInfo><title>Immunogenic characterization of the chimeric surface antigen 1 and 2 (SAG1/2) of Toxoplasma gondii expressed in the yeast Pichia pastoris</title></titleInfo><name type="personal"><namePart type="given">YL</namePart><namePart type="family">Lau</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lau YL et al. Immunogenic characterization of the chimeric surface antigen 1 and 2 (SAG1/2) of Toxoplasma gondii expressed in the yeast Pichia pastoris. Parasitol Res 2011; 109: 871–878.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>109</number></detail><extent unit="pages"><start>871</start><end>878</end></extent></part><relatedItem type="host"><titleInfo><title>Parasitol Res</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>109</number></detail><extent unit="pages"><start>871</start><end>878</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0082"><titleInfo><title>Whole Pichia pastoris yeast expressing measles virus nucleoprotein as a production and delivery system to multimerize Plasmodium antigens</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Jacob</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jacob D et al. Whole Pichia pastoris yeast expressing measles virus nucleoprotein as a production and delivery system to multimerize Plasmodium antigens. PLoS ONE 2014; 9: e86658.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>e86658</start></extent></part><relatedItem type="host"><titleInfo><title>PLoS ONE</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>e86658</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0083"><titleInfo><title>Invasion‐inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen‐1 expressed in Pichia pastoris yeast</title></titleInfo><name type="personal"><namePart type="given">EC</namePart><namePart type="family">Vicentin</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Vicentin EC et al. Invasion‐inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen‐1 expressed in Pichia pastoris yeast. Infect Immun 2014; 82: 1296–1307.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>82</number></detail><extent unit="pages"><start>1296</start><end>1307</end></extent></part><relatedItem type="host"><titleInfo><title>Infect Immun</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>82</number></detail><extent unit="pages"><start>1296</start><end>1307</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0084"><titleInfo><title>Norovirus capsid protein expressed in yeast forms virus‐like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Xia</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Xia M et al. Norovirus capsid protein expressed in yeast forms virus‐like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts. J Med Virol 2007; 79: 74–83.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>74</start><end>83</end></extent></part><relatedItem type="host"><titleInfo><title>J Med Virol</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>79</number></detail><extent unit="pages"><start>74</start><end>83</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0085"><titleInfo><title>Pichia pastoris as a host system for transformations</title></titleInfo><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Cregg</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Cregg JM et al. Pichia pastoris as a host system for transformations. Mol Cell Biol 1985; 5: 3376–3385.</note><part><date>1985</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>3376</start><end>3385</end></extent></part><relatedItem type="host"><titleInfo><title>Mol Cell Biol</title></titleInfo><part><date>1985</date><detail type="volume"><caption>vol.</caption><number>5</number></detail><extent unit="pages"><start>3376</start><end>3385</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0086"><titleInfo><title>GI‐5005, a yeast vector vaccine expressing an NS3‐core fusion protein for chronic HCV infection</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Habersetzer</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Habersetzer F et al. GI‐5005, a yeast vector vaccine expressing an NS3‐core fusion protein for chronic HCV infection. Curr Opin Mol Ther 2009; 11: 456–462.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>456</start><end>462</end></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Mol Ther</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>456</start><end>462</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0087"><titleInfo><title>Baker's yeast expressing the Japanese encephalitis virus envelope protein on its cell surface: induction of an antigen‐specific but non‐neutralizing antibody response</title></titleInfo><name type="personal"><namePart type="given">B</namePart><namePart type="family">Upadhyaya</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Manjunath</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Upadhyaya B, Manjunath R. Baker's yeast expressing the Japanese encephalitis virus envelope protein on its cell surface: induction of an antigen‐specific but non‐neutralizing antibody response. Yeast 2009; 26: 383–397.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>383</start><end>397</end></extent></part><relatedItem type="host"><titleInfo><title>Yeast</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><extent unit="pages"><start>383</start><end>397</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0088"><titleInfo><title>Stabilizing membrane proteins through protein engineering</title></titleInfo><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Scott</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Scott DJ et al. Stabilizing membrane proteins through protein engineering. Curr Opin Chem Biol 2013; 17: 427–435.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>427</start><end>435</end></extent></part><relatedItem type="host"><titleInfo><title>Curr Opin Chem Biol</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><extent unit="pages"><start>427</start><end>435</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0089"><titleInfo><title>Directed evolution of proteins for increased stability and expression using yeast display</title></titleInfo><name type="personal"><namePart type="given">MW</namePart><namePart type="family">Traxlmayr</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Obinger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Traxlmayr MW, Obinger C. Directed evolution of proteins for increased stability and expression using yeast display. Arch Biochem Biophys 2012; 526: 174–180.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>526</number></detail><extent unit="pages"><start>174</start><end>180</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Biochem Biophys</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>526</number></detail><extent unit="pages"><start>174</start><end>180</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0090"><titleInfo><title>Improving recombinant eukaryotic membrane protein yields in Pichia pastoris: the importance of codon optimization and clone selection</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">Oberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Oberg F et al. Improving recombinant eukaryotic membrane protein yields in Pichia pastoris: the importance of codon optimization and clone selection. Mol Membr Biol 2011; 28: 398–411.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>398</start><end>411</end></extent></part><relatedItem type="host"><titleInfo><title>Mol Membr Biol</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><extent unit="pages"><start>398</start><end>411</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0091"><titleInfo><title>Targeting the unfolded protein response in neurodegeneration: a new approach to therapy</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Halliday</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GR</namePart><namePart type="family">Mallucci</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Halliday M, Mallucci GR. Targeting the unfolded protein response in neurodegeneration: a new approach to therapy. Neuropharmacology 2014; 76(Pt A): 169–174.</note><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><detail type="issue"><caption>no.</caption><number>Pt A</number></detail><extent unit="pages"><start>169</start><end>174</end></extent></part><relatedItem type="host"><titleInfo><title>Neuropharmacology</title></titleInfo><part><date>2014</date><detail type="volume"><caption>vol.</caption><number>76</number></detail><detail type="issue"><caption>no.</caption><number>Pt A</number></detail><extent unit="pages"><start>169</start><end>174</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0092"><titleInfo><title>In Pichia pastoris, growth rate regulates protein synthesis and secretion, mating and stress response</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Rebnegger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rebnegger C et al. In Pichia pastoris, growth rate regulates protein synthesis and secretion, mating and stress response. Biotechnol J 2013; 9: 511–525.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>511</start><end>525</end></extent></part><relatedItem type="host"><titleInfo><title>Biotechnol J</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>9</number></detail><extent unit="pages"><start>511</start><end>525</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0093"><titleInfo><title>Quantitative comparison of dynamic physiological feeding profiles for recombinant protein production with Pichia pastoris</title></titleInfo><name type="personal"><namePart type="given">O</namePart><namePart type="family">Spadiut</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Spadiut O et al. Quantitative comparison of dynamic physiological feeding profiles for recombinant protein production with Pichia pastoris. Bioprocess Biosyst Eng 2013; 36: 1571–1577.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>1571</start><end>1577</end></extent></part><relatedItem type="host"><titleInfo><title>Bioprocess Biosyst Eng</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>1571</start><end>1577</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0094"><titleInfo><title>Effects of temperature shifts and oscillations on recombinant protein production expressed in Escherichia coli</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Jazini</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Herwig</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Jazini M, Herwig C. Effects of temperature shifts and oscillations on recombinant protein production expressed in Escherichia coli. Bioprocess Biosyst Eng 2013; 36: 1571–1577.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>1571</start><end>1577</end></extent></part><relatedItem type="host"><titleInfo><title>Bioprocess Biosyst Eng</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>36</number></detail><extent unit="pages"><start>1571</start><end>1577</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0095"><titleInfo><title>The implementation of a design of experiments strategy to increase recombinant protein yields in yeast (review)</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Bora</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bora N et al. The implementation of a design of experiments strategy to increase recombinant protein yields in yeast (review). Methods Mol Biol 2012; 866: 115–127.</note><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>866</number></detail><extent unit="pages"><start>115</start><end>127</end></extent></part><relatedItem type="host"><titleInfo><title>Methods Mol Biol</title></titleInfo><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>866</number></detail><extent unit="pages"><start>115</start><end>127</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0096"><titleInfo><title>Developing a scalable model of recombinant protein yield from Pichia pastoris: the influence of culture conditions, biomass and induction regime</title></titleInfo><name type="personal"><namePart type="given">WJ</namePart><namePart type="family">Holmes</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Holmes WJ et al. Developing a scalable model of recombinant protein yield from Pichia pastoris: the influence of culture conditions, biomass and induction regime. Microb Cell Fact 2009; 8: 35.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>35</start></extent></part><relatedItem type="host"><titleInfo><title>Microb Cell Fact</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>35</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0097"><titleInfo><title>A dynamic method based on the specific substrate uptake rate to set up a feeding strategy for Pichia pastoris</title></titleInfo><name type="personal"><namePart type="given">C</namePart><namePart type="family">Dietzsch</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Dietzsch C et al. A dynamic method based on the specific substrate uptake rate to set up a feeding strategy for Pichia pastoris. Microb Cell Fact 2011; 10: 14.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>14</start></extent></part><relatedItem type="host"><titleInfo><title>Microb Cell Fact</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>14</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0098"><titleInfo><title>GFP‐based optimization scheme for the overexpression and purification of eukaryotic membrane proteins in Saccharomyces cerevisiae</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Drew</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Drew D et al. GFP‐based optimization scheme for the overexpression and purification of eukaryotic membrane proteins in Saccharomyces cerevisiae. Nat Protoc 2008; 3: 784–798.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>784</start><end>798</end></extent></part><relatedItem type="host"><titleInfo><title>Nat Protoc</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>3</number></detail><extent unit="pages"><start>784</start><end>798</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0099"><titleInfo><title>Mapping the yeast host cell response to recombinant membrane protein production: relieving the biological bottlenecks</title></titleInfo><name type="personal"><namePart type="given">MP</namePart><namePart type="family">Ashe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RM</namePart><namePart type="family">Bill</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ashe MP, Bill RM. Mapping the yeast host cell response to recombinant membrane protein production: relieving the biological bottlenecks. Biotechnol J 2011; 6: 707–714.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>707</start><end>714</end></extent></part><relatedItem type="host"><titleInfo><title>Biotechnol J</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>707</start><end>714</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0100"><titleInfo><title>Engineering of glycosylation in yeast and other fungi: current state and perspectives</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">De Pourcq</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">De Pourcq K et al. Engineering of glycosylation in yeast and other fungi: current state and perspectives. Appl Microbiol Biotechnol 2010; 87: 1617–1631.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><extent unit="pages"><start>1617</start><end>1631</end></extent></part><relatedItem type="host"><titleInfo><title>Appl Microbiol Biotechnol</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>87</number></detail><extent unit="pages"><start>1617</start><end>1631</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0101"><titleInfo><title>GPCR production in a novel yeast strain that makes cholesterol‐like sterols</title></titleInfo><name type="personal"><namePart type="given">SM</namePart><namePart type="family">Kitson</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Kitson SM et al. GPCR production in a novel yeast strain that makes cholesterol‐like sterols. Methods 2011; 55: 287–292.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>287</start><end>292</end></extent></part><relatedItem type="host"><titleInfo><title>Methods</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>55</number></detail><extent unit="pages"><start>287</start><end>292</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0102"><titleInfo><title>Enhanced membrane protein expression by engineering increased intracellular membrane production</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Guerfal</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Guerfal M et al. Enhanced membrane protein expression by engineering increased intracellular membrane production. Microb Cell Fact 2013; 12: 122.</note><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>122</start></extent></part><relatedItem type="host"><titleInfo><title>Microb Cell Fact</title></titleInfo><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>12</number></detail><extent unit="pages"><start>122</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0103"><titleInfo><title>Relieving the first bottleneck in the drug discovery pipeline: using array technologies to rationalize membrane protein production</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Bonander</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RM</namePart><namePart type="family">Bill</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bonander N, Bill RM. Relieving the first bottleneck in the drug discovery pipeline: using array technologies to rationalize membrane protein production. Expert Rev Proteomics 2009; 6: 501–505.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>501</start><end>505</end></extent></part><relatedItem type="host"><titleInfo><title>Expert Rev Proteomics</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>6</number></detail><extent unit="pages"><start>501</start><end>505</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0104"><titleInfo><title>Design of improved membrane protein production experiments: quantitation of the host response</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Bonander</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bonander N et al. Design of improved membrane protein production experiments: quantitation of the host response. Protein Sci 2005; 14: 1729–1740.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>1729</start><end>1740</end></extent></part><relatedItem type="host"><titleInfo><title>Protein Sci</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><extent unit="pages"><start>1729</start><end>1740</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0105"><titleInfo><title>Protein trafficking, ergosterol biosynthesis and membrane physics impact recombinant protein secretion in Pichia pastoris</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Baumann</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baumann K et al. Protein trafficking, ergosterol biosynthesis and membrane physics impact recombinant protein secretion in Pichia pastoris. Microb Cell Fact 2011; 10: 93.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>93</start></extent></part><relatedItem type="host"><titleInfo><title>Microb Cell Fact</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>93</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0106"><titleInfo><title>Altering the ribosomal subunit ratio in yeast maximizes recombinant protein yield</title></titleInfo><name type="personal"><namePart type="given">N</namePart><namePart type="family">Bonander</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bonander N et al. Altering the ribosomal subunit ratio in yeast maximizes recombinant protein yield. Microb Cell Fact 2009; 8: 10.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>10</start></extent></part><relatedItem type="host"><titleInfo><title>Microb Cell Fact</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>8</number></detail><extent unit="pages"><start>10</start></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="jphp12353-cit-0107"><titleInfo><title>Increasing gene dosage greatly enhances recombinant expression of aquaporins in Pichia pastoris</title></titleInfo><name type="personal"><namePart type="given">K</namePart><namePart type="family">Norden</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Norden K et al. Increasing gene dosage greatly enhances recombinant expression of aquaporins in Pichia pastoris. BMC Biotechnol 2011; 11: 47.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>47</start></extent></part><relatedItem type="host"><titleInfo><title>BMC Biotechnol</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>11</number></detail><extent unit="pages"><start>47</start></extent></part></relatedItem></relatedItem><identifier type="istex">F6E11952D083724F50B9D5C02407D6ED37EEEB39</identifier><identifier type="ark">ark:/67375/WNG-KM1XJXHK-3</identifier><identifier type="DOI">10.1111/jphp.12353</identifier><identifier type="ArticleID">JPHP12353</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2015 Royal Pharmaceutical Society© 2014 Royal Pharmaceutical Society</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-15</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-KM1XJXHK-3/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000913 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000913 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F6E11952D083724F50B9D5C02407D6ED37EEEB39
|texte= Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?
}}
| This area was generated with Dilib version V0.6.33. |  |